Cystatin C: A Dual Marker for Kidney Function and Cardiovascular Risk

PDF for Printing

Cystatin C has emerged as a clinically useful biomarker that bridges the fields of nephrology and cardiology. Originally studied as a sensitive indicator of kidney function, cystatin C has also demonstrated robust associations with cardiovascular disease (CVD) and mortality. Its utility may extend well beyond the limitations of serum creatinine, particularly in aging populations and those with comorbidities.

What is Cystatin C?

Cystatin C is a 13-kDa protein produced by all nucleated cells at a constant rate. It is freely filtered by the glomeruli, reabsorbed, and almost entirely catabolized in the proximal tubules, without being secreted back into circulation. This makes it an ideal endogenous marker for glomerular filtration rate (GFR), independent of muscle mass, diet, or gender—unlike serum creatinine. As my patients are all being directed to supplement with creatine for healthy muscle mass and brain health, we have a superior marker for estimating GFR (eGFR) independent of whether or not they supplement with creatine!

In clinical practice, cystatin C is used either alone or in combination with creatinine to estimate GFR (eGFR), especially when creatinine may be misleading.

Cystatin C vs. Creatinine in Estimating GFR

Several studies have validated the superior performance of cystatin C in estimating true renal function. Unlike creatinine, which is affected by age, sex, race, and muscle mass, cystatin C levels remain stable across these variables. This allows more accurate estimation of mild-to-moderate kidney dysfunction, particularly in older adults, patients with low muscle mass, or those with chronic illnesses.

A key study by Svensson-Färbom et al. (2014) showed that cystatin C was a stronger predictor of cardiovascular events and mortality than creatinine-based eGFR. The addition of cystatin C significantly improved reclassification of risk categories for cardiovascular events, particularly in those with mildly reduced kidney function (PMID: 24279862).

Cystatin C as a Cardiovascular Risk Marker

In addition to renal function, cystatin C has shown consistent associations with cardiovascular outcomes—independent of traditional risk factors like hypertension, lipids, and diabetes. Here are a couple of studies that correlate cystatin C levels and coronary heart disease:

Ix et al. (2007) – Heart and Soul Study: This pivotal study involved patients with established coronary heart disease (CHD). Elevated cystatin C levels were strongly and independently associated with increased risk of cardiovascular mortality, myocardial infarction, and heart failure. Importantly, these associations persisted after adjusting for creatinine, CRP, and other cardiovascular risk markers (PMID: 17190862).
van der Laan et al. (2016) – Meta-Analysis and Mendelian Randomization: In a meta-analysis of 16 cohorts (~76,000 subjects), observational data showed that each doubling of cystatin C was associated with an 82% higher risk of coronary heart disease (CHD). However, when analyzed through Mendelian randomization, which accounts for genetic determinants of cystatin C, no causal relationship with CHD was found (PMID: 27561768).

This discrepancy suggests that cystatin C is a powerful biomarker of risk, but not a direct mediator of disease. Elevated levels likely reflect underlying pathological processes such as early kidney dysfunction, systemic inflammation, or vascular injury.

How I am Using Cystatin C effective 08/2025:

1. Risk Stratification in Primary Prevention:

In asymptomatic individuals, cystatin C can identify those at higher cardiovascular risk, even when creatinine-based eGFR is normal. This allows for earlier intervention through lifestyle change, blood pressure control, or our cardiovascular health protocol...

2. Improved eGFR in the Elderly and those with Higher Lean Body Mass:

Cystatin C is especially useful in the elderly, where sarcopenia may lead to falsely reassuring creatinine levels. More accurate eGFR leads to better decisions on medication dosing and risk counseling.

3. Heart Failure and Critical Illness Prognosis

Studies like Helmersson-Karlqvist et al. (2022) have shown that cystatin C measured at ICU admission predicts long-term cardiovascular mortality better than creatinine. In the outpatient setting, however, cystatin C combined with NTproBNP will help risk stratify those with either early heart failure as well as diastolic dysfunction. It will help assess regenerative medicine protocols to reverse early heart failure.

A Note & Final Thoughts:

While cystatin C is a valuable biomarker, clinicians should interpret elevated levels in context. Thyroid dysfunction, corticosteroid use, and systemic inflammation can affect cystatin C levels. Also, while its association with CVD is robust, therapeutically targeting cystatin C itself is not useful—it is a surrogate marker, not a causal agent.

Cystatin C is a versatile and reliable metric that enhances the estimation of kidney function and provides meaningful insight into cardiovascular risk. Its superiority over creatinine in multiple clinical scenarios makes it a valuable tool, particularly in patients with ambiguous renal function, advanced age, or established cardiovascular disease.

While not causally linked to cardiovascular pathology, elevated cystatin C is a powerful signal of systemic risk. All physicians should consider its integration into routine risk assessment, especially for patients at intermediate or unclear risk based on traditional markers.

References:

Svensson-Färbom P, et al. Cystatin C–based risk prediction of cardiovascular disease in the community. Circ Cardiovasc Genet. 2014;7(5):677–684. PMID: 24279862
van der Laan SW, et al. Cystatin C and cardiovascular disease: a Mendelian randomization study. J Am Coll Cardiol. 2016;68(9):934–945. PMID: 27561768
Ix JH, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure. Circulation. 2007;115(2):173–179. PMID: 17190862
Helmersson-Karlqvist J, et al. Admission cystatin C predicts long-term cardiovascular mortality in ICU patients. Heart. 2022;108(4):279–285. BMJ Journal
West M, et al. Cystatin C and incident cardiovascular disease in modern cohorts. J Am Heart Assoc. 2022. AHA Journal

Gary E. Foresman, MD.

Back to blog